Rain Oncology IncChange company Symbol lookupSelect an option...RAIN Rain Oncology IncLQR LQR House IncFCX Freeport-McMoRan IncXBIO Xenetic Biosciences IncTBCPW Thunder Bridge Capital Partners III Equity Warrant Exp 01 Feb 2025 *W EXP 02/01/2025HGKGY Power Assets Holdings LtdICPT Intercept Pharmaceuticals IncKEY KeyCorpTTWO Take-Two Interactive Software IncTOPS Top Ships IncGo
Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.
|
|
|
|
| |
Company Profile
Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 0.42x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Avanish VellankiChmn.
- Robert DoebelePres.
- Joy BruceCFO
- Franklin M. Berger
- Aaron I. Davis
Address
- 8000 Jarvis Avenue, Suite 204
- Newark, CA 94560
- Phone: (510) 953-5559
- https://www.rainoncology.com/
Insider Trading
During the most recent quarter, 1M shares were bought, and 995K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.